Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,092 USD | +0.90% |
|
+3.54% | +24.25% |
12/07 | UBS Raises Price Target on Regeneron Pharmaceuticals to $1,250 From $1,124, Maintains Buy Rating | MT |
11/07 | Morgan Stanley Trims Price Target on Regeneron Pharmaceuticals to $1,182 From $1,183 | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.25% | 117B | |
+20.28% | 127B | |
+25.44% | 27.67B | |
-18.45% | 20.33B | |
-15.17% | 16.79B | |
-15.91% | 15.63B | |
+12.74% | 14.84B | |
-47.10% | 14.65B | |
+56.68% | 14.43B | |
+147.18% | 12.49B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Transcript : Regeneron Pharmaceuticals, Inc. Presents at JPMorgan 40th Annual Healthcare Conference, Jan-10-2022 10